$BFYT - $IMMU - On our trading list with news today or analyst comments with our opinion & trade ideas.Congrats to all our followers in Benefytt that got BOUGHT OUT today! Big gains there! Also Immunomedics expands deal with Roche.Benefytt Technologies to be acquired by MDP Funds for $31.00 per shareBenefytt Technologies announced that it has entered into a definitive agreement to be acquired by funds affiliated with Madison Dearborn Partners. The all-cash transaction is structured as a tender offer of $31.00 per share that will commence in the coming days, followed immediately by a merger. The announced transaction with the MDP Funds is the culmination of a process led by Benefytt's Board of Directors since July 26, 2019, to explore, review and evaluate a range of potential strategic alternatives for the Company. The tender offer price per share represents a 59% premium over the 30-day volume-weighted average price per share of Benefytt's common stock through the close of trading on July 10, 2020. The Company's Board has unanimously approved the acquisition of the Company by the MDP Funds.Our Take: Congratulations if you were in this one!!Immunomedics expands collaboration with Roche to evaluate Trodelvy and Tecentriq Immunomedics (IMMU) announced an extension of its current clinical collaboration with Roche (RHHBY) to evaluate Trodelvy, Immunomedics' anti-Trop-2 ADC, in combination with Tecentriq, Roche's programmed cell death ligand 1, or PD-L1-blocking, checkpoint inhibitor, or CPI, in patients with metastatic urothelial cancer, or mUC, and metastatic non-small cell lung cancer, or mNSCLC. Under the terms of the extension, Roche will be conducting two open-label, multicenter, randomized Phase 1b/2 studies using its MORPHEUS platform. The MORPHEUS-mUC study will randomize CPI-naive mUC patients who have failed platinum-containing chemotherapy to receive the Tecentriq plus Trodelvy combination or Tecentriq alone. The second study, Morpheus-Lung, will enroll CPI-experienced mNSCLC patients after failure with platinum-based regimen to receive either Tecentriq and Trodelvy or docetaxel alone. Separately, Immunomedics also announces that the new Phase 2 NeoSTAR study initiated by Aditya Bardia at Mass General Cancer Center has enrolled the first patient with localized triple-negative breast cancer to receive Trodelvy before surgery to remove the tumor. Pathological complete response rate is the primary endpoint of this study, with disease-free survival and overall survival serving as secondary endpoints.Our Take: One of our favorites that continues to impress with it's pipeline development. Also good to have 'big pockets' behind this companies research. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try. Trade Try2BeFunded today! .